Xinhua Pharmaceutical announced on October 19. Recently, the company received the “Drug Supplement Application Approval Notice” for nimodipine tablets approved and issued by the State Drug Administration. The product passed the consistent evaluation of generic drug quality and efficacy. As a continuing treatment after prior use of nimodipine injection, this product can prevent and treat ischemic nerve damage caused by cerebrovascular spasms after aneurysm subarachnoid hemorrhage; it can also be used to treat senile brain dysfunction.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.